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Abstract 17 
A misguided inflammatory response is frequently implicated in myelin damage. Particularly 18 
prominent among myelin diseases, multiple sclerosis (MS) is an autoimmune condition, with 19 
immune–mediated damage central to its aetiology. Nevertheless, a robust inflammatory response is 20 
also essential for the efficient regeneration of myelin sheaths after such injury. Here, we discuss the 21 
functions of inflammation that promote remyelination, and how these have been experimentally 22 
disentangled from the pathological facets of the immune response. We focus on the contributions that 23 
resident microglia and monocyte-derived macrophages make to remyelination and compare the roles 24 
of these two populations of innate immune cells. Finally, the current literature is framed in the 25 
context of developing therapies that manipulate the innate immune response to promote 26 
remyelination in clinical myelin disease. 27 
1 Remyelination: regeneration in the CNS 28 
The mammalian central nervous system (CNS) is often considered an archetypal example of a tissue 29 
with poor regenerative potential. This is exemplified by clinical conditions such as spinal cord injury, 30 
stroke and Alzheimer’s disease, where prognosis is poor due to limited regeneration of neurons and 31 
axons (1). Myelin sheaths, however, are an important exception to this dogma, being a component of 32 
the CNS that can regenerate robustly with good functional outcome; a process termed remyelination 33 
(2). 34 
 35 
Myelin sheaths are made up of layers of lipid-rich dielectric membrane wrapped around axons to 36 
which they provide electrical insulation and trophic support (3). This membrane is produced by 37 
specialised glial cells: oligodendrocytes in the CNS, or Schwann cells in the peripheral nervous 38 
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system (PNS). The loss of myelin sheaths with preservation of the underlying axon is known as 39 
demyelination. This is sometimes referred to as primary demyelination to distinguish it from 40 
secondary demyelination, where myelin loss occurs as a consequence of axonal loss. This latter 41 
process is more accurately referred to as Wallerian degeneration, and we regard the use of the term 42 
demyelination in this situation as confusing and misleading. 43 
 44 
Remyelination involves the reinvestment of new myelin sheaths around intact axons from which they 45 
have been lost (i.e. demyelination) (2). This process is performed by newly generated 46 
oligodendrocytes that derive from a pool of oligodendrocyte progenitor cells (OPCs) following a 47 
demyelinating insult. OPCs are present throughout both grey and white matter in the CNS, and have 48 
“stem cell-like” properties such as multipotency and self-renewal (4). In response to demyelination, 49 
OPCs proliferate and migrate to the lesion site (5,6) where they differentiate to mature 50 
oligodendrocytes or Schwann cells, extending processes to remyelinate denuded axons (7). 51 
Consequently, saltatory conduction is restored (8) and axons are generally protected from further 52 
degeneration (9). In some paradigms, whilst axons are not fully protected, their degeneration is 53 
substantially delayed with motor deficits not re-appearing until much later timepoints (10). 54 
 55 
Whilst originally characterised in animal models (11), remyelination is also seen in human patients 56 
with MS (12). Amongst MS lesions there is an associated between remyelination and preservation of 57 
axons (13), although it is in practice difficult to asses whether remyelination occurs because axons 58 
have survived, or the axons have survived because they are remyelinated. Whilst extensive in some 59 
cases, remyelination efficiency falls as the disease progresses, so it is usually insufficient to prevent a 60 
patient’s neurological decline as damage gradually accumulates (14,15). 61 
 62 
Crucially, regenerative processes become less efficient with increasing age, and remyelination is no 63 
exception (16). This tenet of regenerative medicine is particularly relevant in a chronic disease such 64 
as MS, which spans several decades (17). Ageing brings about intrinsic changes in OPCs (18) and 65 
their environmental signals (19), both of which negatively impact remyelination. Because of this age-66 
related decline, many key findings have come from comparing remyelination or clinical outcome in 67 
young and old animals (18,19,20) or human cases (21). More interventional approaches have 68 
manipulated these systems to identify pathways crucial for efficient remyelination in young animals 69 
(22,23,24) or that can rejuvenate remyelination in older animals (25, 26). 70 
 71 
When remyelination fails, the limiting step is most commonly OPC differentiation, a term 72 
encompassing the establishment of axonal contact, activation of myelin synthesis pathways and the 73 
wrapping and compaction of the newly generated sheath (4). In humans, this is evidenced by an 74 
abundance of undifferentiated oligodendrocyte lineage cells in many chronic MS lesions, which fail 75 
to remyelinate (27,28). Thus, there is much clinical need for therapies to enhance OPC differentiation 76 
and endogenous remyelination. One avenue for this is to target the innate immune system. 77 
2 Innate immune cells of the CNS 78 
The immune system is the network of cellular and molecular elements that protect an organism from 79 
disease. In vertebrates, it can broadly be divided into the innate and the adaptive immune systems, 80 
though these two branches communicate extensively and various components, such as innate 81 
lymphoid cells, share features of both. In general, the innate immune system responds rapidly and 82 
relatively non-specifically to infection or damage, whilst the adaptive immune system mounts a 83 
slower, long-lasting response to specific targets. Inflammation describes an immune-mediated 84 
response to stimuli that are perceived as harmful, such as invading pathogens or tissue damage. 85 
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 86 
Like other tissues, the CNS has its own battalion of resident tissue macrophages, called microglia. 87 
These are innate immune cells that, in the healthy brain, serve physiological functions in synaptic 88 
plasticity (29) and clearance of debris (30). Meanwhile, microglia continuously survey their 89 
microenvironment for stimuli that might indicate injury or infection, and are ready to respond to this 90 
by entering an activated state characterised by cytokine secretion, phagocytosis and, on occasions, 91 
direct cytotoxicity (31). 92 
 93 
After such a stimulus, microglia may be supplemented by a second population of macrophages from 94 
the periphery. These differentiate from blood monocytes that have infiltrated the CNS in response to 95 
tissue damage, and thus originate in the bone marrow. Key differences exist between resident 96 
microglia and these monocyte-derived macrophages, including their disparate developmental origins 97 
(32), their transcriptomic signatures (33) and capacity for local self-renewal and expansion (34). 98 
However, in a demyelinated lesion, both cell types show high levels of activation and only recently 99 
have successful attempts been made to phenotypically and functionally distinguish between them, as 100 
will be discussed. 101 
 102 
Besides microglia and monocyte-derived macrophages, an array of other innate immune cells can be 103 
found in a demyelinating lesion. Whilst neutrophils (35), mast cells (36) and dendritic cells (37) can 104 
contribute to demyelination, with a disputed role of natural killer cells in promoting/limiting damage 105 
(38), little evidence exists to support a substantial contribution of these cell types to remyelination 106 
(39). Thus, in our discussion of CNS remyelination and the innate immune system, our focus is 107 
primarily on microglia and infiltrating macrophages. 108 
3 Innate immune cells and myelin disease 109 
In MS, aberrant activity of the innate immune system can contribute to myelin damage. The driver of 110 
this is a defective adaptive immune response involving autoreactive T cells, but through innate-111 
adaptive cross talk, microglia and monocyte-derived macrophages can be recruited and mediate a 112 
substantial part of the damage (40). Based on this aetiology, clinical therapies for MS tend to focus 113 
on inhibiting the adaptive immune system. Examples include the monoclonal antibodies natalizumab, 114 
which impairs T cell trafficking into the CNS (41), and rituximab, which targets CD20 to deplete 115 
autoantibody-producing B cells (42). 116 
 117 
A commonly used range of models for MS is experimental autoimmune encephalomyelitis (EAE), in 118 
which an inoculated animal develops autoreactive T-cells targeting myelin. This is a useful paradigm 119 
for modelling many of the immunogenic features of MS (43). However, the complex inflammatory 120 
pathogenesis of these models can mask beneficial regenerative effects of the innate immune system 121 
that may occur concurrently with negative, disease-contributing innate cell functions. As such, 122 
delineating specific regenerative functions of innate cells and signals in EAE is challenging. In 123 
contrast, toxin-induced models of demyelination, such as focal lysolecithin injection, have more 124 
discrete phases of demyelination and remyelination. As the myelin damage is initiated directly by the 125 
toxin, we can generally assume that immune cell activity during the remyelination phase is a 126 
response to myelin damage, rather than an on-going cause. We will see how such a response can 127 
indeed contribute to the process of remyelination. 128 
4 The critical role of the innate immune system 129 
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Making use of these toxin-induced demyelination models, a beneficial role of the innate immune 130 
system in remyelination was demonstrated in rats depleted of circulating monocytes (22). This was 131 
achieved by systemic treatment with clodronate liposomes, which are toxic to cells that phagocytose 132 
them. Treated animals had fewer inflammatory cells in the lesion suggesting a muted innate immune 133 
response to tissue damage and, interestingly, a lower proportion of their axons were remyelinated 134 
post-lesion. 135 
 136 
Conversely, by promoting inflammation it is possible to increase the efficiency of myelin formation. 137 
This was shown by using transplanted OPCs to myelinate retinal ganglion cell axons, which are 138 
normally unmyelinated prior to where they form the optic nerve (44). Administration of the Toll-Like 139 
Receptor 2 agonist zymosan greatly increased the number of activated macrophages and the degree 140 
of myelination by the transplanted OPCs. Thus the link between an inflammatory response and 141 
remyelination has been shown in both “loss-of-function” and “gain of function” experiments. 142 
 143 
A beneficial role of the innate immune system in remyelination is less clear-cut in models where 144 
inflammation also contributes to the damage. In EAE, similar to MS, both microglia and infiltrating 145 
monocytes are implicated in demyelination (45,46,47). However, evidence also suggests that subsets 146 
of these cells can play beneficial roles in limiting damage and promoting remyelination. 147 
Macrophages can modulate their phenotypes in response to extracellular cues (48), often termed 148 
“M1” (pro-inflammatory) or “M2” (anti-inflammatory) polarisation for convenience, though in 149 
reality representing a spectrum with a broad degree of plasticity (49). A shift towards the anti-150 
inflammatory M2 phenotype is associated with a milder clinical picture in EAE (50), and 151 
administration of M2-polarised monocytes to EAE animals can enhance differentiation of 152 
oligodendrocytes and improve symptoms (51). This is consistent with a crucial shift from pro- to 153 
anti-inflammatory phenotypes in remyelination of toxin-induced lesions (25). Myeloid-derived 154 
suppressor cells are a subpopulation of innate immune cells that typically express M2 markers and 155 
limit damage in EAE at peaks of disability, in part by promoting apoptosis of T lymphocytes (52). 156 
 157 
Thus, even on a backdrop of inflammatory damage, cells of the innate immune system can play 158 
beneficial roles in outcome and may contribute to remyelination. This is important for the application 159 
of findings from toxin-induced models to the immune-mediated pathology of MS. Indeed, post-160 
mortem data from MS patients, shows a correlation between the density of macrophages and the 161 
density of OPCs within a lesion (53). MS lesions can be classified by their histopathology: active 162 
plaques, which have on-going inflammation, show the highest levels of OPC recruitment and 163 
remyelination, whilst chronic active and chronic inactive plaques show little inflammation and 164 
remyelination is rare (54). Lesions that remyelinate successfully become shadow plaques, in which 165 
axons are relatively preserved. Reactivation of inflammation in chronic plaques may be a strategy to 166 
overcome their remyelination failure (2). 167 
 168 
The decline of remyelination efficiency with age also occurs in part at the level of the innate immune 169 
system. This was demonstrated using a heterochronic parabiosis system, in which mice of different 170 
ages are connected via their circulatory systems (26). Remyelination of a toxin-induced lesion is 171 
rejuvenated in old mice that are exposed to the systemic environment of a younger mouse. The effect 172 
was abrogated in mice that lacked CCR2, a receptor necessary for monocyte entry into the CNS, 173 
suggesting that young macrophages are able to stimulate old OPCs to differentiate more efficiently. 174 
A timely shift from pro- to anti-inflammatory innate immune cell phenotypes is important for 175 
efficient remyelination (25), a phenomenon also seen in regeneration of other tissues, including skin 176 
(55). This shift is diminished with ageing, but rejuvenated by heterochronic parabiosis (25), and 177 
appears to be instrumental in the rejuvenation of remyelination. 178 
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 179 
The positive relationship between remyelination and inflammation is strikingly similar to results seen 180 
across a broad range of regeneration paradigms. Healing of other murine tissues such as skin (56) is 181 
impaired when macrophages are subject to selective genetic ablation. The famously extensive 182 
regrowth of salamander limbs after amputation is also diminished when macrophages are depleted by 183 
a toxic liposome treatment (57). Even in the planarian flatworm, a remarkable organism capable of 184 
regenerating any of its tissues after transection, primitive macrophage-like cells are abundant at the 185 
site of injury (58). The conservation of this phenomenon across the animal kingdom gives further 186 
weight to the idea that remyelination requires a robust inflammatory response. 187 
5 How do innate immune cells contribute to remyelination? 188 
The most important functions of innate immune cells in remyelination appear to be 1) phagocytosis 189 
of debris and 2) secretion of growth signals, cytokines and other factors. Through a combination of 190 
these mechanisms, microglia and monocyte-derived macrophages can fashion a pro-regenerative 191 
environment that maximises the potential of OPCs to differentiate and replace the myelin on denuded 192 
axons (Fig. 1). 193 
 194 
Macrophages are well known for their phagocytosis of invading pathogens, cellular debris and 195 
apoptotic host cells. In a lesion where myelin sheaths are destroyed, much of this phagocytic 196 
response is directed towards fragments of myelin, which can linger in the environment. CNS myelin 197 
inhibits OPC differentiation in vitro (59) and in vivo it was shown that remyelination is impaired if a 198 
lesion is supplemented with additional myelin debris (60). This would suggest that clearance of 199 
myelin debris by phagocytosis is necessary for OPCs to produce new oligodendrocytes. More direct 200 
evidence for this comes from recent studies showing reduced remyelination when phagocytosis is 201 
specifically impaired in microglia (CX3CR1 knockout, (23)) or in infiltrating macrophages (LysM-202 
specific RXRα knockout, (24)). 203 
 204 
Inflammation can also contribute to remyelination through phagocytosis-independent mechanisms. 205 
This is apparent during the enhanced myelination of retinal ganglion cells by transplanted OPCs 206 
when inflammation is stimulated (44). These axons are not myelinated under normal conditions, so 207 
there is accordingly no myelin debris for innate immune cells to clear. Innate immune cells can 208 
secrete a wide array of factors that contribute to the lesion environment, and these are disturbed in 209 
older animals, which have a lower capacity for remyelination (19,20). The ability of microglia-210 
conditioned media to modulate OPC behaviour in vitro is further evidence of secreted factors 211 
promoting remyelination. Media conditioned by pro-inflammatory M1 microglia, which appear soon 212 
after a lesion, promote OPC proliferation, whilst media conditioned by M2 anti-inflammatory 213 
microglia, which peak later, prevent apoptosis and encourage differentiation to oligodendrocytes 214 
(25). 215 
 216 
Several specific factors are known to be produced during inflammation and promote remyelination. 217 
Insulin-like growth factor (IGF-1) and transforming growth factor-β (TGF-β) have long been known 218 
to promote OPC differentiation in vivo (61,62) and their expression is delayed in the slow 219 
remyelination of old rats (20). More recently, endothelin 2 was identified by transcriptional profiling 220 
of the OPC retinal transplant model (63) and activin-A was found to be essential for the microglia-221 
conditioned media effects on OPC differentiation (25). The msh-like homeobox-3 gene (Msx3) 222 
appears to be an important positive regulator for the M2 phenotype and for expression of activin-A 223 
and IGF-1. Overexpression of Msx3 in transplanted microglia enhances remyelination in both EAE 224 
and lysolecithin models (64). 225 
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6 Divergent roles for macrophages and microglia 226 
The two key functions of phagocytosis and mediator secretion can be carried out by both resident 227 
microglia and infiltrating macrophages, which are often discussed as a single functional population. 228 
However, as our models of remyelination and the tools to probe them become more sophisticated, 229 
more differences between these two pools of innate immune cells are emerging. 230 
 231 
A comparison of the transcriptomes of microglia and peripherally-derived macrophages revealed 232 
several hundred genes that could distinguish between the two populations, largely related to sensing 233 
endogenous ligands and microbes (33). This may become less pronounced when microglia become 234 
activated in a lesion environment, as inflammatory stimuli can substantially alter the microglial 235 
transcriptome (65). Nevertheless, it is possible to determine the origin of innate immune cells in EAE 236 
lesions based on maintained molecular signatures: notably, the microglial-specific surface markers 237 
P2ry12, FCRLS (66) and Tmem119 (67) are maintained during inflammation, and are not 238 
upregulated in monocyte-derived macrophages. Prior to these recent advances, the use of blood-brain 239 
barrier impermeable toxins have been used to specifically ablate peripherally-derived macrophages, 240 
whilst fluorescent bone-marrow chimeras have allowed peripheral cells to be tracked upon entry to 241 
the CNS. 242 
 243 
These techniques have demonstrated how microglia and infiltrating macrophages have a high degree 244 
of overlap in their function. Microglia appear to undergo a compensatory proliferation in lesions 245 
lacking monocyte-derived macrophages due to peripheral ablation (68). Using a green fluorescent 246 
protein-positive (GFP+) bone marrow chimaera, it was shown that the transition from M1 to M2 247 
phenotypes occurs similarly in both microglia and infiltrating macrophages after a lysolecithin-248 
induced lesion (25). The infiltration of young monocytes into an old lesion in the heterochronic 249 
parabiosis model accelerates the shift from M1 dominance to M2 dominance within the lesion and 250 
likely contributes to the enhanced remyelination. Relatively few cells in the lesion were derived from 251 
a GFP+ young partner, suggesting that these infiltrating cells were influencing endogenous innate 252 
immune cells to create a pro-regenerative environment. 253 
 254 
Other experiments have elucidated divergent functions of microglia and monocyte-derived 255 
macrophages in remyelination. When demyelination was induced by dietary cuprizone, blocking 256 
peripheral monocyte infiltration by CCR2 deficiency was inconsequential to the regenerative process 257 
(23), in contrast to the importance of this process for efficient remyelinating of a sterotactic 258 
lysolecithin lesion (26). Endogenous microglia, on the other hand, were shown to be vital as 259 
remyelination was impaired in a CX3CR1 microglial receptor knockout mouse model. In the dietary 260 
cuprizone model, demyelination occurs without the blood-brain barrier damage of stereotactic 261 
injection (69), which may account for the reduced role of monocyte-derived macrophages, though 262 
these cells were still able to infiltrate the lesioned CNS (23). Additionally this study did not look at 263 
ageing, which may be a context in which CCR2-dependent monocyte recruitment becomes more 264 
critical.  Divergent roles for endogenous and infiltrating components were also observed when EAE 265 
was induced in transgenic mice with green CX3CR2+ microglia and red CCR2+ macrophages (70). 266 
In this case, highly activated monocyte-derived macrophages appear to initiate demyelination, whilst 267 
microglia had more beneficial roles in clearing debris. 268 
 269 
This rapidly expanding body of evidence is leading us away from a model of a single 270 
macrophage/microglia compartment in a demyelinated lesion. Significant transcriptional differences 271 
in sensome genes (33) suggest that the two populations can respond differently to the same 272 
environmental stimuli. The manifestation of these differences seems to depend strongly on the 273 
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experimental model, perhaps implying that differences in age or blood-brain barrier function are 274 
important (23,26). In EAE, where the pathology is immune-mediated, infiltrating macrophages and 275 
resident microglia may even have opposing roles, promoting de- and re-myelination respectively 276 
(70). However, this result contrasts with a beneficial effect of specifically blocking resident 277 
microglial activation, even in EAE with the same immunogen (46). In any case, the high variability 278 
between experimental setups suggests that the relative contributions of these two innate immune cell 279 
populations will likely differ between individual clinical myelin disorders, their stages and lesion 280 
types. 281 
7 Inflammatory therapies for regeneration in myelin disease? 282 
A range of clinical diseases involve primary demyelination, the causes of which can be intrinsic or 283 
extrinsic to the oligodendrocyte lineage. Intrinsic causes account for the leukodystrophies, in which 284 
genetic mutations affect production of myelin proteins and other oligodendrocyte functions. 285 
Alternatively, the pathology can originate from the oligodendrocytes’ environment, for example 286 
inflammation in MS, or toxicity as in many model systems. Whilst cell therapy is a promising avenue 287 
for leukodystrophies, diseases that originate externally will most likely benefit from interventions 288 
that lessen the demyelinating insult and promote endogenous remyelination (2). 289 
 290 
Currently, most disease-modifying drugs used to treat MS focus on modulating the adaptive immune 291 
response using small molecules or monoclonal antibodies. These can be effective in reducing the 292 
length and frequency of relapses and provide symptomatic relief, though there is limited impact on 293 
the progressive phase of the disease and no curative agents are currently in clinical use (71). 294 
Modulating the innate immune response to promote endogenous remyelination is a potential means 295 
to salvage denuded axons and prevent progression of the disease. 296 
 297 
Microglia and infiltrating macrophages promote remyelination through important roles in debris 298 
clearance and secretion of factors into their local environment. These two functions become 299 
gradually less efficient as an animal ages (26,24,20), though aspects of the decline appear to be 300 
reversible by altering the tissue environment (72). Compelling evidence from parabiosis shows that 301 
remyelination by previously inefficient OPCs in an old animal can indeed be rejuvenated by 302 
manipulating components of the innate immune system (26). Systemic pharmacological activation of 303 
the innate immune system has also been shown to promote remyelination (73). Additionally, as we 304 
learn more about the differences between microglia and monocyte-derived macrophages, divergent 305 
roles may be specifically targeted to enhance the production of a pro-regenerative environment. 306 
 307 
However, the immune system is a complex network with much cross-talk between its adaptive and 308 
innate branches. Translational challenges will come in being able to stimulate the beneficial functions 309 
of innate immune cells without simultaneously fuelling further autoimmune destruction of myelin 310 
sheaths. Additionally, many of the symptoms of MS result from the death of axons that have already 311 
been too long without the trophic support and protection of myelin (74). Endogenous remyelination 312 
could not reverse the symptoms associated with previous axonal death, though it could salvage 313 
vulnerable axons at the point between demyelination and death. As such, remyelinating therapies 314 
would address an important unmet need in the treatment of demyelinating disease. Such regenerative 315 
therapies will likely be additive and complementary to the current disease-modifying treatments that 316 
can reduce the occurrence of demyelination with variable risks of adverse effects. 317 
 318 
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Despite foreseeable challenges, harnessing the pro-regenerative properties of inflammation has 319 
shown extensive benefit in animal models of remyelination. This approach has the potential to 320 
partially reverse the course of MS when it begins to makes the transition from bench to bedside.  321 
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Figure legends 541 
Figure 1: Innate immune cells in a demyelinated lesion can derive from activation of CX3CR1+ 542 
resident ramified microglia (green). Alternatively they may originate from blood monocytes (pink), 543 
which are recruited from the circulation in a CCR2-dependent manner and differentiate into 544 
macrophages. CX3CR1 and CCR2 have proved useful for genetically labeling or ablating the 545 
separate populations. Once activated, these cells become difficult to distinguish based on morphology 546 
and classical immunohistochemical techniques (striped), though some surface markers have recently 547 
been observed specifically in microglia, including Tmem119, P2ry12 and FCRLS. Innate immune 548 
cells can phagocytose inhibitory myelin debris and secrete an array of pro-regenerative factors, some 549 
of which are positively regulated by the transcription factor Msx3.  The combination of these 550 
functions promotes the differentiation of OPCs (purple) and subsequent reinvestment of new myelin 551 
sheaths around denuded axons (blue). 552 
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